When your literature search produces hundreds or even thousands of results, you may find yourself having to look up each gene individually – and the process quickly goes from painstakingly slow to impossible.
With BioReflect, we have designed an at-a-glance and up-to-date global overview of publications, with topic-based clustering that lets you breeze through your literature searches with ease and in an unbiased manner. BioReflect can fast-track your preparation for regulatory approval or exploratory reading by helping you to select the most important relevant scientific literature, and by easily linking literature directly to your data for easy scientific exploration.
In addition, BioReflect seamlessly integrates disease, gene and chemical annotations in its reported results, and therefore can help reveal gene-disease associations and more from publications. BioReflect is a valuable tool across your project lifecycles – from initial exploration phases to patents and clinical trial searches.
BioLizard is proud to have received the Best Poster Award at the European Society for Spatial Biology (ESSB) conference, recognising our work on benchmarking cell segmentation methods for single-cell spatial transcriptomics.
Paul Vauterin has transitioned from Chief Technology Officer (CTO) to Chief Operating Officer (COO) at BioLizard, reflecting a shift in focus towards helping organisations integrate AI into their operations and unlock greater value from their data.
For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])
